Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of SD-101 Cream in Epidermolysis Bullosa
NCT07482813Phase 3Not yet recruiting
- Sponsor
- Paradigm Therapeutics, Inc.
- Start
- Nov 2026
- Primary completion
- Sep 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
01
Overview
A Phase 3 trial of allantoin in epidermolysis bullosa (EB), sponsored by Paradigm Therapeutics, Inc.. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
allantoin
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT07482813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07482813.